CJC-1295 Complete Guide: Dosing, Benefits, DAC vs No DAC, and the Ipamorelin Stack (2026)

CJC-1295 is one of the most widely used peptides in the growth hormone optimization space — and for good reason. As a synthetic analog of growth hormone-releasing hormone (GHRH), it amplifies your body's own GH pulses rather than introducing exogenous growth hormone directly. The result is a more physiologically natural increase in GH and IGF-1 levels, with a safety profile that has held up across multiple human clinical trials.

This guide covers everything you need to know: how CJC-1295 works, the critical difference between the DAC and non-DAC forms, dosing protocols, the popular CJC-1295/Ipamorelin stack, side effects, and what the research actually shows.

What Is CJC-1295?

CJC-1295 is a 29-amino acid peptide derived from the first 29 amino acids of endogenous GHRH — the hypothalamic hormone that signals the pituitary gland to release growth hormone. Natural GHRH has a half-life of only 7 minutes in circulation, limiting its therapeutic utility. CJC-1295 was engineered to extend that window dramatically while preserving the core GHRH receptor-binding activity.

It exists in two distinct forms that are often confused:

• CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF 1-29) — half-life of approximately 30 minutes; mimics natural pulsatile GH release
• CJC-1295 with DAC (Drug Affinity Complex) — half-life of 6–8 days; produces sustained, continuous GH elevation

These are fundamentally different molecules with different pharmacology, dosing schedules, and risk profiles. Understanding the distinction is essential before using either.

Mechanism of Action

CJC-1295 works by binding to GHRH receptors on somatotroph cells in the anterior pituitary gland. This binding triggers the synthesis and secretion of growth hormone, which then enters circulation and stimulates the liver to produce insulin-like growth factor 1 (IGF-1).

The key distinction from exogenous HGH injection is that CJC-1295 works upstream of the pituitary, stimulating your own GH release rather than bypassing it. This preserves the natural regulatory feedback loops — including somatostatin, the hormone that puts the brakes on excessive GH secretion — which may contribute to a more favorable safety profile.

A landmark 2006 study published in the Journal of Clinical Endocrinology & Metabolism (Teichman et al.) demonstrated that a single injection of CJC-1295 in healthy adults produced sustained, dose-dependent increases in GH levels lasting up to 6 days, with IGF-1 elevations persisting for 9–11 days. Mean GH concentrations increased 2–10 times above baseline depending on dose.

CJC-1295 with DAC vs. Without DAC: Key Differences

This is the most important distinction for anyone researching CJC-1295, and the source of significant confusion in the peptide community.

CJC-1295 Without DAC (Mod GRF 1-29)

The non-DAC form has a half-life of approximately 30 minutes — long enough to work, short enough to allow GH secretion to follow a pulsatile pattern. This closely mimics the body's natural GHRH rhythm, where GH is released in discrete pulses rather than continuously.

• Half-life: ~30 minutes
• Dosing frequency: 2–3 times daily (typically morning, pre-workout, and before bed)
• Typical dose: 100–200 mcg per injection
• GH pattern: Pulsatile — matches natural physiology
• Best for: Stacking with GHRP/ghrelin mimetics like Ipamorelin

CJC-1295 With DAC

The DAC form uses a Drug Affinity Complex — a lysine residue with a maleimido-propionic acid linker — that allows the peptide to bind reversibly to albumin in the bloodstream. This dramatically extends its circulating half-life to 6–8 days, enabling once-weekly or twice-weekly dosing.

• Half-life: 6–8 days
• Dosing frequency: Once or twice weekly
• Typical dose: 1–2 mg per week
• GH pattern: Sustained, blunted elevation ("GH bleed")
• Best for: Convenience; less suited to stacking with GHRP peptides

Which is better? Most practitioners prefer the non-DAC form (Mod GRF 1-29) because pulsatile GH release is more physiologically normal and allows stacking with Ipamorelin or other GHRPs to amplify the GH pulse. The DAC form's sustained elevation can paradoxically desensitize GHRH receptors over time and may produce more pronounced side effects including water retention and insulin resistance.

Benefits of CJC-1295

The benefits attributed to CJC-1295 stem from elevated GH and IGF-1 levels. Clinical and observational evidence supports the following:

Increased Lean Muscle Mass

GH and IGF-1 are potent anabolic signals that stimulate muscle protein synthesis and satellite cell activation. Users and clinicians report measurable gains in lean body mass over 3–6 month cycles, particularly when combined with resistance training.

Reduced Body Fat

Growth hormone has well-documented lipolytic effects — it promotes the breakdown of stored triglycerides (particularly visceral fat) and shifts metabolism toward fat oxidation. The GH Research Society has noted that GH deficiency correlates with increased central adiposity, and restoration of normal GH levels reverses this tendency.

Improved Sleep Quality

The largest natural GH pulse occurs during slow-wave sleep. CJC-1295 amplifies this nocturnal pulse, and many users report deeper, more restorative sleep as one of the earliest and most noticeable effects — often within the first 1–2 weeks of use.

Enhanced Recovery

Elevated IGF-1 supports collagen synthesis, connective tissue repair, and skeletal muscle regeneration. Athletes using CJC-1295 often cite reduced recovery time between training sessions and faster healing from minor injuries.

Anti-Aging Effects

GH levels decline progressively with age — a phenomenon called somatopause. Restoring GH to youthful levels is associated with improvements in skin thickness, bone density, immune function, and body composition. These are the same rationale behind FDA-approved GH replacement therapy for diagnosed adult GH deficiency.

Dosing Protocols

Dosing varies significantly between the two forms and whether CJC-1295 is used alone or in combination.

Standalone CJC-1295 (No DAC)

• Dose: 100–200 mcg per injection
• Frequency: 2–3 times daily
• Timing: Morning (fasted), pre-workout, and 30–60 min before bed (most important)
• Cycle length: 8–16 weeks on, 4–8 weeks off
• Administration: Subcutaneous injection (abdomen, thigh, or deltoid)

CJC-1295 With DAC

• Dose: 1 mg once weekly, or 500 mcg twice weekly
• Cycle length: 8–12 weeks, with breaks to prevent receptor desensitization

Important timing note: For maximum GH pulse amplitude, inject CJC-1295 (no DAC) in a fasted state — at least 2 hours after the last meal and 30 minutes before eating. Elevated blood glucose and fatty acids blunt GH secretion by stimulating somatostatin release.

The CJC-1295 + Ipamorelin Stack

This is the most commonly used peptide combination in clinical GH optimization protocols, and it represents a genuine pharmacological synergy rather than simple addition.

CJC-1295 (no DAC) stimulates the GHRH receptor, amplifying the magnitude of each GH pulse. Ipamorelin is a selective ghrelin mimetic that stimulates the growth hormone secretagogue receptor (GHSR-1a), independently triggering GH release while simultaneously suppressing somatostatin — the "off switch" for GH secretion.

Together, they act on two separate receptor pathways to produce a GH pulse that is significantly larger and more sustained than either compound alone. Clinical data suggests the combination can increase GH release by 4–8x compared to either peptide individually.

Standard Stack Protocol

• CJC-1295 (no DAC): 100–200 mcg per dose
• Ipamorelin: 200–300 mcg per dose
• Frequency: 2–3 times daily (both peptides injected simultaneously)
• Most important dose: 30–60 minutes before bed
• Cycle: 12 weeks on, 4–8 weeks off

The pre-sleep dose is considered the cornerstone of the protocol because it amplifies the largest natural GH pulse of the day, which occurs during deep sleep. Morning and pre-workout doses provide secondary pulses to support anabolism and fat metabolism during active hours.

For a deeper dive on Ipamorelin's individual mechanisms and standalone protocols, see our Ipamorelin Complete Guide.

Side Effects and Safety

CJC-1295 has a relatively well-characterized safety profile based on human clinical trials, which is more than can be said for most research peptides.

Common Side Effects

• Injection site reactions: Mild redness, swelling, or discomfort — typically transient
• Water retention: Particularly common in the first 1–4 weeks; usually resolves as the body adapts
• Increased appetite: GH is orexigenic; hunger often increases, especially with the DAC form
• Tingling or numbness: Occasionally reported in the extremities, similar to carpal tunnel-like symptoms; more common at higher doses
• Fatigue or drowsiness: Especially noted after the first few doses; often improves
• Flushing: A temporary warmth or flush sensation shortly after injection

Serious Risks

• Insulin resistance: Chronic GH elevation can impair glucose metabolism. Monitoring fasting glucose and HbA1c is advisable during extended use, especially in individuals with metabolic risk factors.
• Carpal tunnel syndrome: More commonly reported with the DAC form due to sustained GH elevation and associated soft tissue fluid retention.
• Pituitary desensitization: Prolonged continuous stimulation may down-regulate GHRH receptors; cycling on/off mitigates this risk.
• Theoretical cancer risk: Elevated IGF-1 is associated with cell proliferation. While no causal link has been established at the doses used clinically, individuals with a personal or family history of hormone-sensitive cancers should exercise caution and consult a physician.

Contraindications

CJC-1295 is not appropriate for individuals with active malignancies, diabetic retinopathy, severe insulin resistance, or those who are pregnant or breastfeeding. Use in individuals under 21 (with open growth plates) is also inadvisable.

Clinical Research Overview

Unlike many peptides sold in the research chemical market, CJC-1295 has actual human trial data — a meaningful distinction.

The pivotal Teichman et al. (2006) study published in JCEM enrolled healthy adults aged 21–61 and administered single subcutaneous doses of CJC-1295 ranging from 30 to 120 mcg/kg. Key findings:

• GH levels increased 2–10 times above baseline in a dose-dependent fashion
• IGF-1 levels increased 1.5–3 times for up to 11 days
• Effects were maintained with multiple doses
• The compound was "safe and relatively well tolerated" across all doses studied

A second study (Jetté et al., JCEM 2005) confirmed similar results with the non-DAC form (Mod GRF 1-29), showing robust GH pulse amplification with subcutaneous dosing.

No phase III efficacy trials have been completed, and CJC-1295 never received FDA approval — development was discontinued before that stage. This means the safety and efficacy data are robust for a research peptide but remain limited compared to approved medications.

Compounding Pharmacies and Legal Status

In the United States, CJC-1295 occupies a complex regulatory space.

The FDA does not approve CJC-1295 for any indication. However, licensed physicians can prescribe it as a compounded medication under 503A or 503B pharmacy frameworks — the same pathways used for compounded semaglutide and other peptides. Compounding pharmacies formulate CJC-1295 in sterile injectable form to physician specifications.

Importantly, the FDA has periodically updated its list of "bulk drug substances" that may or may not be compounded. As of 2025, CJC-1295 (and peptides generally) remain in a contested zone — the FDA proposed restrictions on certain peptides in 2023, and practitioners have pushed back vigorously. The regulatory situation continues to evolve; patients and clinicians should verify current compounding status before initiating therapy.

For legitimate therapeutic use:

• Obtain a prescription from a licensed physician or telehealth provider specializing in hormone optimization
• Use only 503A/503B-accredited compounding pharmacies with USP797 sterile compounding compliance
• Avoid "research chemical" vendors — product quality and sterility cannot be verified

Storage and Reconstitution

CJC-1295 is typically supplied as a lyophilized (freeze-dried) powder that must be reconstituted before use:

• Reconstitution: Add bacteriostatic water slowly along the vial wall; do not shake — swirl gently
• Storage (unreconstituted): 2–8°C refrigerated, or freeze for longer storage; keep away from light
• Storage (reconstituted): Refrigerate at 2–8°C; use within 28–30 days
• Do not freeze reconstituted peptide — freeze-thaw cycles degrade the peptide

Conclusion

CJC-1295 stands out among research peptides for having genuine human clinical data behind it, a well-understood mechanism of action, and a clear rationale for its most popular applications — lean body composition, recovery, sleep quality, and anti-aging. The non-DAC form (Mod GRF 1-29) is generally preferred over the DAC version due to its more physiological pulsatile GH stimulation and superior stackability with Ipamorelin.

For anyone exploring GH optimization, the CJC-1295/Ipamorelin stack represents the current evidence-based standard in peptide-based GH secretagogue protocols — particularly when compared to the cost, side effect profile, and legal complexity of exogenous HGH administration.

As with all compounded peptides, work with a qualified physician, use a reputable sterile compounding pharmacy, and monitor relevant biomarkers (IGF-1, fasting glucose) throughout the protocol.